Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Mosunetuzumab Alone or with Zanubrutinib for the Treatment of Newly Diagnosed Follicular Lymphoma

Trial Status: active

This phase II trial tests how well mosunetuzumab with or without zanubrutinib works in treating patients with newly diagnosed follicular lymphoma. Mosunetuzumab is a “bispecific antibody” designed to help the immune system cells to come close to, and kill cancer cells. A bispecific antibody binds to two different proteins; one found on the surface of cancer cells and one found on the surface of cells in the immune system. An antibody is a protein made by the immune system to help fight infections and other harmful processes/cells/molecules. Scientists developed mosunetuzumab in a laboratory to bind to a cancer cell and a T cell (which plays a key role in the immune system’s fighter response) at the same time. Mosunetuzumab may strengthen the immune system’s ability to fight cancer cells by activating the body's own cells to destroy the tumor. Zanubrutinib, a Bruton tyrosine kinase inhibitor, works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells. Giving mosunetuzumab with or without zanubrutinib may kill more cancer cells in patients with newly diagnosed follicular lymphoma.